Literature DB >> 2420446

Phase II trial of fludarabine in patients with epithelial ovarian cancer.

J J Kavanagh, C A Stringer, L J Copeland, D M Gershenson, P Saul.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1986        PMID： 2420446

Source DB:  PubMed          Journal:  Cancer Treat Rep        ISSN： 0361-5960


× No keyword cloud information.
  4 in total

1.  Adoptive cell therapy with tumor-infiltrating lymphocytes in patients with metastatic ovarian cancer: a pilot study.

Authors:  Magnus Pedersen; Marie Christine Wulff Westergaard; Katy Milne; Morten Nielsen; Troels Holz Borch; Lars Grønlund Poulsen; Helle Westergren Hendel; Mia Kennedy; Gillian Briggs; Stacey Ledoux; Trine Jakobi Nøttrup; Pernille Andersen; Thomas Hasselager; Özcan Met; Brad H Nelson; Marco Donia; Inge Marie Svane
Journal:  Oncoimmunology       Date:  2018-09-26       Impact factor: 8.110

Review 2.  Fludarabine. A review of its pharmacological properties and therapeutic potential in malignancy.

Authors:  S R Ross; D McTavish; D Faulds
Journal:  Drugs       Date:  1993-05       Impact factor: 9.546

3.  Phase II study of fludarabine phosphate in patients with advanced colorectal carcinoma.

Authors:  J A Ajani; J L Abbruzzese; J S Faintuch; R Blackburn; B Levin; B M Boman
Journal:  Invest New Drugs       Date:  1988-04       Impact factor: 3.850

Review 4.  Fludarabine phosphate. A new anticancer drug with significant activity in patients with chronic lymphocytic leukemia and in patients with lymphoma.

Authors:  G Rodriguez
Journal:  Invest New Drugs       Date:  1994       Impact factor: 3.850
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.